United States
Print page content Print
Increase text size Decrease text size
Text Size

FOSTERA® PRRS

For porcine reproductive and respiratory syndrome (PRRS) virus-positive herds, look to Fostera® PRRS to help provide whole-herd protection against both the respiratory and reproductive forms of disease caused by PRRS virus. It’s the first and only modified-live virus (MLV) vaccine that’s licensed for the vaccination of healthy, susceptible swine 1 day of age or older — meaning you can truly protect your herd from start to finish.

Expand All
  • Licensed for whole-herd protection, Fostera PRRS helps protect pigs from PRRS at every production stage.

    • Earliest protection on the market for growing pigs. Fostera PRRS can be administered as early as 1 day of age to aid in preventing reproductive and respiratory diseases caused by PRRS virus in healthy, susceptible swine in PRRS virus-positive herds. Fostera PRRS is demonstrated to improve average daily gain in growing pigs in the face of a PRRS virus challenge so you can get growing pigs to market faster.1-3
    • Helps protect your reproductive herd. In a challenge study, 33 times more piglets were born alive to gilts vaccinated with Fostera PRRS compared with unvaccinated controls.4 This research allowed Fostera PRRS to earn the "aids in preventing" label claim, currently one of the highest available claims granted by the U.S. Department of Agriculture for reproductive disease caused by the PRRS virus.
    • A longer demonstrated duration of immunity (DOI) for the herd. Fostera PRRS has a longer demonstrated 19-week DOI against reproductive disease in sows or gilts vaccinated six weeks prior to breeding than other commercially available vaccines and a 26-week DOI against respiratory disease — demonstrated nine weeks longer than other commercially available PRRS vaccines.
  • Packaging:

    • 50-dose vial — SKU #5357
    • 250-dose vial — SKU #5358

    Directions:
    Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided. Shake well and aseptically administer a single 2-mL dose intramuscularly to pigs 1 day of age or older. Efficacy has not been demonstrated in seropositive piglets. In young pigs, revaccinate after maternally derived antibodies to PRRS have declined. Safety of this product has been demonstrated when sows or gilts are vaccinated prior to breeding or at any stage of pregnancy. Protection against reproductive disease, however, was demonstrated when animals were vaccinated six weeks prior to breeding. Consult your veterinarian for appropriate use and timing of vaccination.

    1. Do not vaccinate boars of breeding age.
    2. Store at 2° to 7° C (35° to 45° F). Do not freeze.
    3. Use entire contents when first opened.
    4. Burn containers and all unused contents.
    5. Sterilized syringes and needles should be used to administer this vaccine.
    6. Do not vaccinate within 21 days before slaughter.
    7. Vaccine virus may be shed and transmitted to other populations of swine in direct or indirect contact with vaccinated swine. The duration of potential vaccine virus transmission may vary. Nonvaccinated pigs in contact with pigs vaccinated with Fostera PRRS may seroconvert to vaccine virus. Use of the vaccine in herds intended to remain PRRS virus-seronegative is contraindicated. Introduction of vaccinated pigs into herds intended to remain PRRS virus-seronegative is contraindicated.
  • 1 Data on file, Study Report No. 13PORKBIO03, Zoetis Inc.
    2 Data on file, Study Report No. 3127R-60-10-890, Zoetis Inc.
    3 Data on file, Study Report No. 3121R-60-10-909, Zoetis Inc.
    4 Data on file, Study Report No. 3127R-60-11-988, Zoetis Inc.

FSTRA-00083